MediCity tenants can also hire technical equipment at BioCity Nottingham to the east of the city centre. This includes the Bruker 400 MHZ NMR system, mass spectrometers, HP Liquid Chromatography system, Gas Chromatography system, centrifuges and freezers.
Situated within the Nottingham Enterprise Zone, the laboratories in MediCity, located in the historic D6 building on the Boots site, were once focussed on the development of well-known brands such as Strepsil. D6, previously also known as the ‘Drys’ factory, manufactured, stored and dispatched pills, tablets, pastilles, powders, toilet requisites and other dry products.
Interest in the new MediCity laboratories has already come from companies engaged in drug development, chewable vitamins and therapeutic cream applications.
Contract product development organisation, Co-Formulate Ltd occupies processing facilities along with office and laboratory space at MediCity. This enables Co-Formulate Ltd. to further expand its services in product development, analytical services and CMC regulatory affairs to support clients across the pharmaceutical, OTC healthcare, medical device and cosmetics industries. The highly-skilled team require the MediCity laboratory space for the growth in analytical services, small scale production and stability testing.
This move marks the return of Huw Jones, Director of Co-Formulate Ltd. to the laboratories he helped design in 1996 as an employee of the former Boots Healthcare International. Huw, said: “Since I left the company and founded Co-Formulate with fellow Director, Nazim Kanji, we have built a client base of leading pharmaceutical and consumer healthcare companies. We are ready to expand and MediCity is the ideal location for us. We can also tap into the MediCity business support and will be looking into the various financial schemes open to Nottingham life science companies.”
David Browning, Director of MediCity, says: “Companies like Co-Formulate are looking for competitively-priced laboratories and offices so this is the ideal base to start and grow a venture, including those which might have very particular needs. Not only do they benefit from Enterprise Zone rate relief but also become part of a growing centre of excellence in health, beauty and wellness innovation.”
Ged O’Shea, Director of Product Development at Boots, says: “We anticipate that MediCity will create opportunities for Boots UK to work with new partners and it is really encouraging to see the growth in interest in MediCity and the new tenants in the D6 building.”
Situated within the Nottingham Enterprise Zone, the laboratories in MediCity, located in the historic D6 building on the Boots site, were once focussed on the development of well-known brands such as Strepsil. D6, previously also known as the ‘Drys’ factory, manufactured, stored and dispatched pills, tablets, pastilles, powders, toilet requisites and other dry products.
Interest in the new MediCity laboratories has already come from companies engaged in drug development, chewable vitamins and therapeutic cream applications.
Contract product development organisation, Co-Formulate Ltd occupies processing facilities along with office and laboratory space at MediCity. This enables Co-Formulate Ltd. to further expand its services in product development, analytical services and CMC regulatory affairs to support clients across the pharmaceutical, OTC healthcare, medical device and cosmetics industries. The highly-skilled team require the MediCity laboratory space for the growth in analytical services, small scale production and stability testing.
This move marks the return of Huw Jones, Director of Co-Formulate Ltd. to the laboratories he helped design in 1996 as an employee of the former Boots Healthcare International. Huw, said: “Since I left the company and founded Co-Formulate with fellow Director, Nazim Kanji, we have built a client base of leading pharmaceutical and consumer healthcare companies. We are ready to expand and MediCity is the ideal location for us. We can also tap into the MediCity business support and will be looking into the various financial schemes open to Nottingham life science companies.”
David Browning, Director of MediCity, says: “Companies like Co-Formulate are looking for competitively-priced laboratories and offices so this is the ideal base to start and grow a venture, including those which might have very particular needs. Not only do they benefit from Enterprise Zone rate relief but also become part of a growing centre of excellence in health, beauty and wellness innovation.”
Ged O’Shea, Director of Product Development at Boots, says: “We anticipate that MediCity will create opportunities for Boots UK to work with new partners and it is really encouraging to see the growth in interest in MediCity and the new tenants in the D6 building.”
ENDS